We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look ...

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Merck boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone accounts for around 50 ...

Merck boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone accounts for ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year. After an explosive opening marked by a suite of ...

In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans to overcome high-profile losses of exclusivity (LOEs) slated to dent sales through the end of the ...

To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Merck & Co.’s Keytruda is the world’s best-selling drug and has been a cancer juggernaut for more than a ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

Executives at Amgen made the case for MariTide’s differentiation, while Merck’s CEO contended that Keytruda’s coming loss of exclusivity can be managed. SAN FRANCISCO — For any hopes the dealmaking ...

“Statins and PCSK9 inhibitors are phenomenal meds and we have so much evidence that they can reduce risk, but we see a huge gap in patients receiving them,” says Amit Khera, vice president of ...

Conversely, in the FinnGen database, LDLR agonists (OR [95% CI] = 1.394 [1.036, 1.875], p = 0.028) and PCSK9 inhibitors (OR [95% CI] = 1.404 [1.098, 1.795], p = 0.007) were significantly associated ...